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Effect of ageing on female fertility
Introduction
It is well recognised that the fertility of women de-
creases with age. The decline starts at 30 years of age
and fertility becomes minimal by 45 years of age.1
This phenomenon has been observed for both natural
conception and assisted reproduction. A pioneering
study of natural conception investigated a group of
Hutterite women, who belonged to a Protestant sect
that condemns the practice of contraception.2 The mean
age of the last confinement was 41 years and the inter-
val between confinements increased with advancing
maternal age, thus indicating the decline in fecundity
with increasing age.2
There is evidence that the chance of success of
infertility treatment also decreases with advancing
age.3-10 In studies of artificial insemination, the cumu-
lative pregnancy rates have been shown to decrease
significantly as the ages of the women increase.3-6 The
pregnancy rates achieved by in vitro fertilisation (IVF)
and gamete intrafallopian transfer have also been
shown to decrease with increasing age.7-10 There are
no local data, however, on the effect of ageing on the
outcome of assisted reproduction. In this study, we have
analysed the IVF cycles initiated during a 10-year
period to assess the effect of ageing on the success of
IVF treatment in Hong Kong Chinese women.
Materials and methods
The records of the 1336 IVF cycles that were initi-
ated in 771 women between 1 January 1986 and 31
December 1995 in the Department of Obstetrics and
Gynaecology at the Queen Mary Hospital (QMH) were
analysed. Up until late 1989, ovarian stimulation was
achieved by using clomifene (clomiphene) citrate and
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Objective. To analyse the effect of ageing on female fertility in an in vitro fertilisation programme in Hong Kong.
Design. Retrospective study.
Setting. University teaching hospital, Hong Kong.
Patients. Seven hundred and seventy-one women in whom 1336 cycles of in vitro fertilisation were initiated
between 1 January 1986 and 31 December 1995.
Main outcome measures. Patient age and indications for treatment; hormonal response; and the number of can-
celled cycles, oocytes retrieved, oocytes fertilised, cleaving embryos, embryos transferred, and clinical pregnancies.
Results. Compared with women aged ≤30 years (n=193), women aged ≥36 years (n=398) had a significantly higher
cycle cancellation rate (19.3% versus 10.4%), fewer oocytes retrieved per retrieval cycle (6.6 versus 9.0), fewer
oocytes fertilised per retrieval cycle (5.0 versus 7.0), fewer cleaving embryos per retrieval cycle (4.8 versus 6.8), and
lower serum oestradiol level (9735 [standard deviation, 5681] pmol/L versus 10 708 [5916] pmol/L) despite a larger
amount of human menopausal gonadotrophin having been used (all variables, P<0.01; Chi squared test). The clinical
pregnancy rate per initiated cycle (range, 7.5%-13.0%) decreased with advancing age (P<0.01; Chi squared test).
Conclusion. Ageing has a significant deleterious effect on women’s reproductive capability. Women should be
encouraged to seek early medical advice and treatment for subfertility.
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human menopausal gonadotrophins (HMGs). There-
after, it was achieved by inducing downregulation with
gonadotrophin-releasing hormone (GnRH) agonists
and then by giving HMG (the ‘long’ protocol). A course
of intranasal buserelin (Suprefact; Hoechst AG, Frank-
furt, Germany) 150 µg four times daily was started on
day 21 of the menstrual cycle preceding the treatment
cycle. On day 2 of the treatment cycle, pelvic ultra-
sonography was performed and blood was taken to
assess the 17-β-oestradiol (E2) level. Treatment was
started if no abnormality was detected by ultrasono-
graphy and when the E2 level was <220 pmol/L. The
regimen consisted of intramuscular HMG 150 IU and
follicle-stimulating hormone (FSH) 150 IU on days 3
and 4. From day 5 onwards, intramuscular HMG was
given at a dosage of 150 IU/d. The ovarian response
was monitored by measuring the serum E2 level and
by performing pelvic ultrasonography. The dosage
of HMG was increased if the ovarian response was
unsatisfactory after at least 1 week of treatment. In
patients with a history of poor ovarian response in
previous treatment cycles, the ‘short’ protocol was
used. In this protocol, buserelin therapy was started
on day 2 of the treatment cycle.
Human chorionic gonadotrophin (HCG) 10 000 IU
was given intramuscularly in the evening when the
leading follicle was ≥18 mm in diameter, the serum E2
level was >1100 pmol/L per leading follicle, and when
there were at least three follicles with a diameter
>15 mm. Treatment was discontinued if the ovarian
response was poor or if a spontaneous surge in the
luteinizing hormone (LH) level occurred. Oocytes
were retrieved 36 to 38 hours after HCG injection and
incubated for 4 to 6 hours before insemination. Up to
four cleavage-stage embryos were transferred approxi-
mately 40 hours after insemination. Embryo transfer
was cancelled if there was a failure in oocyte retrieval,
fertilisation, or cleavage, or if there was an excessive
risk of ovarian hyperstimulation syndrome.
The luteal phase of the cycle was supported by
giving two booster doses of HCG (1500 IU) 5 days
apart. If the serum E2 level was >18 000 pmol/L before
the administration of the ovulating dose of HCG or
>7340 pmol/L during the luteal phase, or if there
was clinical evidence of ovarian hyperstimulation,
vaginal progesterone pessaries (Cyclogest; Cox
Pharmaceuticals, Barnstaple, United Kingdom) 200 mg
twice daily were given instead.
Patients were classified into the following three
age-groups: ≤30 years, 31-35 years, and ≥36 years.
The effect of ageing on the following factors was
analysed: cycle cancellation rate, oocyte response,
serum oestradiol level on the day of the administra-
tion of the ovulating dose of HCG, and the number of
ampoules of HMG used per cycle. Clinical pregnancy
was defined as either the detection of the presence of
gestational sac(s) on ultrasound scans or histological
evidence of gestational products. Success rates were
expressed as the number of clinical pregnancies per
initiated cycle, per oocyte retrieval cycle, and per em-
bryo transfer cycle. Statistical analyses were performed
using the Chi squared or Kruskal-Wallis test.
Results
The mean age of the 771 women studied was 33.7 years
(standard deviation [SD], 3.1 years; range, 21-43
years). Of the 1336 IVF cycles, 193 (14.4%) were ini-
tiated in women aged 30 years or younger, 745 (55.8%)
cycles in women aged 31 to 35 years, and 398 (29.8%)
cycles in those aged 36 years and older. Table 1 shows
the indications for IVF in the different age-groups.
Tubo-peritoneal problems, pelvic endometriosis, and
male-factor infertility constituted the major causes of
subfertility among the couples involved. Table 2 shows
the number of initiated and cancelled cycles, and the
number of oocyte retrievals and embryo transfers. Of
the 1336 initiated cycles, 184 (13.8%) were cancelled
because of poor ovarian response or spontaneous LH
surge. The cancellation rate varied significantly with
age (P<0.01), rising from 10.4% in women aged ≤30
years to 19.3% in those aged ≤36 years. A total of 1152
cycles of oocyte retrieval (86.2% of initiated cycles)
Table 1. Indications for in vitro fertilisation
Indications No. of cycles (%)
Age-group (years)
≤30, 31-35, ≥36, All ages,
n=193 n=745 n=398 n=1336
Tubo-peritoneal 137 (71.0)  454 (60.9) 244 (61.3)  835 (62.5)
Pelvic endometriosis 18 (9.3) 85 (11.4) 60 (15.1) 163 (12.2)
Male-factor infertility 15 (7.8) 85 (11.4) 34 (8.5) 134 (10.0)
Idiopathic 13 (6.7) 72 (9.7) 32 (8.0) 117 (8.8)
Tubal + male-factor infertility 5 (2.6) 13 (1.7) 19 (4.8) 37 (2.8)
Others 5 (2.6) 36 (4.8) 9 (2.3) 50 (3.7)
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were performed, and 1003 (87.1%) of these cycles
involved subsequent embryo replacement.
The ovarian responses, arranged according to
age-group, are shown in Table 3. Advancing age had a
significantly adverse effect on the number of follicles
aspirated (P<0.01), the number of oocytes retrieved
(P<0.01), the number of oocytes fertilised (P<0.01),
and the number of cleaving fertilised oocytes (P<0.01).
The overall fertilisation rate was 75.5%, and the rate
did not differ significantly among the three age-groups
(P=0.37). The overall cleavage rate was 96.9% and
was not affected by age (P=1.00).
The number of ampoules of HMG used in the
initiated cycles increased significantly with advanc-
ing age (P<0.01) [Table 4]. The average number of
ampoules used per initiated cycle increased from 28.2
in women aged ≤30 years to 36.3 in those aged ≥36
years. Furthermore, the serum E2 level achieved just
before the administration of the ovulating dose of
HCG decreased significantly with advancing age
(P<0.01), dropping from 10 708 (SD, 5916) pmol/L in
women aged ≤30 years to 8306 (4865) pmol/L in those
aged ≥36 years (Table 4).
There were a total of 146 clinical pregnancies.
The overall clinical pregnancy rate per initiated cycle
was 10.9% and the rate decreased significantly with
advancing age (P<0.05) [Table 5]. The clinical preg-
nancy rates per oocyte retrieval cycle and per embryo
transfer cycle also showed a falling trend with increas-
ing age of the women. However, the differences were
not statistically significant (Table 5).
Table 2. Details of in vitro fertilisation cycles
Cycles Age-group (years) P value*
≤30 31-35 ≥36 All ages
No. of initiated cycles 193 745 398 1336
No. of cancelled cycles 20 (10.4%) 87 (11.7%) 77 (19.3%) 184 (13.8%) <0.01
(% of initiated cycles)
No. of oocyte retrievals 173 (89.6%) 658 (88.3%) 321 (80.7%) 1152 (86.2%) <0.01
(% of initiated cycles)
No. of embryo transfers 154 (89.0%) 574 (87.2%) 275 (85.7%) 1003 (87.1%) <0.01
(% of oocyte retrieval cycles)
* P values comparing age-groups ≤30 and ≥36 years (χ2 test)
Table 3. Ovarian responses during in vitro fertilisation cycles
Age-group (years) P value*
≤30 31-35 ≥36 All ages
No. of follicles aspirated 2219 (12.8) 7752 (11.8) 2921 (9.1) 12 892 (11.2) <0.01
(No. per oocyte retrieval cycle)
No. of oocytes retrieved 1560 (9.0) 5468 (8.3) 2108 (6.6) 9136 (7.9) <0.01
(No. per oocyte retrieval cycle)
No. of oocytes fertilized 1213 (7.0) 4117 (6.3) 1594 (5.0) 6924 (6.0) <0.01
(No. per oocyte retrieval cycle)
Fertilisation rate 78.4% 75.4% 74.1% 75.5% 0.37
No. of fertilized oocytes cleaved 1173 (6.8) 4024 (6.1) 1549 (4.8) 6746 (5.9) <0.01
(No. per oocyte retrieval cycle)
Cleavage rate 95.9% 97.4% 96.6% 96.9% 1.00
No. of embryos transferred 461 (3.0) 1656 (2.9) 843 (3.1) 2960 (3.0)
(No. per embryo transfer cycle)
* P values comparing age-groups ≤30 and ≥36 years (χ2 test)
Table 4. Hormonal response during in vitro fertilisation
Age-group (years) P value*
≤30 31-35 ≥36 All ages
Serum oestradiol level on day of
HCG† treatment
(Mean [SD]) (pmol/L) 10 708 (5916) 10 176 (5865) 8306 (4865) 9735 (5681) <0.01
No. of ampoules of HMG‡ used
per initiated cycle 28.2 30.9 36.3 32.1 <0.01
* P values comparing age-groups ≤30 and ≥36 years (χ2 test)
† HCG human chorionic gonadotrophin
‡ HMG human menopausal gonadotrophin
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Discussion
The results of this retrospective analysis show that
the cancellation rate (19.3%) for the women aged 36
years and older in the IVF programme at the QMH
was almost double that for the women aged 30 years
or younger (10.4%). Because the long buserelin pro-
tocol was used in most of the ovarian stimulation
cycles, spontaneous LH surges were rare and most of
the cancellations were caused by poor ovarian re-
sponse. In those who underwent oocyte retrieval, the
number of oocytes obtained and the peak serum E2
levels were significantly lower in the older women,
despite more ampoules of HMG being used in these
women. Hence, older women had a poorer ovarian re-
sponse to gonadotrophin stimulation. Possible mech-
anisms underlying this poor ovarian response include
progressive follicular depletion and declining follicular
competence with advancing age, which correlate with
the decrease in the level of inhibin and increase in
the level of FSH in the later reproductive years.11,12
The fertilisation and embryo cleavage rates were
similar among the three age-groups. Because the
number of oocytes obtained per cycle decreased sig-
nificantly with increasing age, the number of embryos
obtained per cycle (range, 4.8-6.8) also decreased
significantly. In the IVF programme at the QMH, a
maximum of four embryos is replaced. Consequently,
there was no difference in the number of embryos
replaced among the three age-groups. However, the
clinical pregnancy rates per cycle of oocyte retrieval
and per cycle of embryo transfer showed a decreasing
trend with advancing age, although this result was not
statistically significant for this small sample. The sat-
isfactory pregnancy rates and lower miscarriage rates
that have been achieved in older women receiving
oocytes from young donors have led to the postulation
that female reproductive ageing is due to declining
oocyte quality.1,13-15 Whereas some studies of oocyte
donation have found lower pregnancy rates in the older
recipients compared with the younger recipients,16-18
other studies have shown that this effect can be
corrected by increasing the doses of oestrogen or
progesterone in the recipients’ stimulation pro-
tocols.19,20 It  is thus likely that the age-related decline
in fecundity is primarily a result of the ageing oocytes,
rather than a reduction in endometrial receptivity,
which may be a contributing factor but is likely to be
remediable by the hormone stimulation provided in
the stimulation protocols.
The dosage of gonadotrophins used in the IVF
programme at the QMH is adjusted according to the
ovarian response. A higher initial dose is not used in
the cycles for older women, because not all women
older than 35 years have poor ovarian response, and
excessive ovarian stimulation by gonadotrophins can
result in ovarian hyperstimulation syndrome. Factors
other than the age of the woman might predict poor
ovarian response in IVF treatment; they include a
family history of premature ovarian failure, a history
of pelvic surgery on the adnexa, endometriosis, obes-
ity, idiopathic infertility, and smoking.21 Chan et al22
have shown that high basal FSH levels are associated
with a worse response to ovarian stimulation in IVF
treatment. There is also evidence that a low level
of plasma inhibin23,24 and a relatively high level of
early follicular phase E225-27 are associated with a poor
ovarian response. The clomifene test, which measures
the ovary’s ability to control FSH secretion, helps to
predict which women would respond well to stimula-
tion and which would respond badly.21 Chang et al28
have recently suggested that there is an age-related
decrease in the number of antral follicles. Hence,
measuring the number of antral follicles might be
helpful in predicting a patient’s response to ovarian
stimulation.
Various therapeutic strategies have been tried to
improve the success of patients who have poor response
to the conventional long protocols of ovarian stimula-
tion. The use of the short GnRH protocol—that is,
simultaneously giving an GnRH analogue and gonado-
trophins—takes advantage of the initial hormonal
‘flare-up’ produced by the analogues. Conversely,
reducing the dose of the GnRH analogue, with the
aim of reducing the intensity of pituitary suppression,
Table 5. Clinical pregnancy rates
Age-group (years) P value*
≤30 31-35 ≥36 All ages
No. of clinical pregnancies 25 91 30 146
Clinical pregnancy rate (%)
per initiated cycle 13.0 12.2 7.5 10.9 0.03
per oocyte retrieval cycle 14.5 13.8 9.3 12.7 0.11
per embryo transfer cycle 16.2 15.9 10.9 14.6 0.13
* P values comparing age-groups ≤30 and ≥36 years (χ2 test)
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has been reported to result in lower cycle cancellation
rates and better ovarian responses.29 Preliminary data
have also shown that using recombinant gonado-
trophins may result in the production of more oocytes
and more embryos compared with when gonado-
trophins derived from urinary extraction is used.30,31
Further studies are necessary to show whether these
drugs can achieve better responses in poor responders.
Oocyte donation from young women is a valid alter-
native for women who have poor ovarian reserve.
In modern society, women tend to defer marriage
and postpone child-bearing. This trend, together with
the fact that fertility decreases with advancing age, have
posed challenges to doctors involved in the treatment
of infertility. Women should be educated and informed
of the decline in fertility with ageing and the compara-
tively low cost-effectiveness of assisted reproduction
treatment in the older age-groups. They should be
encouraged to promptly seek medical advice for
subfertility, so that investigations can be performed
and treatment given at an early stage. The option of
receiving donated oocytes to improve the success of
IVF in older women should also be explained.
References
1. Navot D, Bergh PA, Williams MA, et al. Poor oocyte quality
rather than implantation failure as a cause of age-related
decline in female fertility. Lancet 1991;337:1375-7.
2. Tietze C. Reproductive span and rate of reproduction among
Hutterite women. Fertil Steril 1957;8:89-97.
3. Schwartz D, Mayaux MJ. Female fecundity as a function of
age: results of artificial insemination in 2193 nulliparous
women with azoospermic husbands. Federation CECOS. N
Engl J Med 1982;306:404-406.
4. Shenfield F, Doyle P, Valentine A, Steele SJ, Tan SL. Effects of
age, gravidity and male infertility status on cumulative con-
ception rates following artificial insemination with cryopreserved
donor semen: analysis of 2998 cycles of treatment in one centre
over 10 years. Hum Reprod 1993;8:60-4.
5. Stovall DW, Toma SK, Hammond MG, Talbert LM. The
effect of age on female fecundity. Obstet Gynaecol 1991;77:
33-6.
6. Wong AW, Ho PC, Kwan M, Ma HK. Factors affecting the
success of artificial insemination by frozen donor semen.
Int J Fertil 1989;34:25-9.
7. Tan SL, Royston P, Campbell S, et al. Cumulative conception
and livebirth rates after in-vitro fertilisation. Lancet 1992;
339:1390-4.
8. Piette C, Mouzon J, Bachelot A, Spira A. In-vitro fertilisation:
influence of women’s age on pregnancy rates. Hum Reprod
1990;5:56-9.
9. Wood C, Calderon I, Crombie A. Age and fertility: results
of assisted reproductive technology in women over 40 years
J Assist Reprod Genet 1992;9:482-4.
10. Harrison KL, Breen TM, Hennessey JF, et al. Patient age
and success in a human IVF programme. Aust NZ J Obstet
Gynaecol 1989;29:326-8.
11. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson
JF. Accelerated disappearance of ovarian follicles in mid-life:
implications for forecasting menopause. Hum Reprod 1992;
7:1342-6.
12. Speroff L. The effect of ageing on fertility. Curr Opin Obstet
and Gynecol 1994;6:115-20.
13. Serafini P, Tran C, Tan T, Norbryn G, Batzofin J. Oocyte
ageing is the main factor responsible for the decline in
fertility with chronological advancement. Evidence from
the IVF surrogacy and egg donation programs. Proceedings
of the 48th Annual Meeting of the American Fertility
Society;1993; New Orleans, US. New Orleans: American
Fertility Society;1993:A011.
14. Navot D, Drews MR, Bergh PA, et al. Age-related decline in
female fertility is not due to diminished capacity of the uterus
to sustain embryo implantation. Fertil Steril 1994;61:97-101.
15. Abdalla HI, Burton G, Kirkland A, et al. Age, pregnancy and
miscarriage: uterus versus ovarian factors. Hum Reprod 1993;
8:1512-7.
16. Yaron Y, Botchan A, Amit A, Kogosowski A, Yovel I, Lessing
JB. Endometrial receptivity: the age-related decline in preg-
nancy rates and the effect of ovarian function. Fertil Steril
1993;60:314-8.
17. Levran D, Ben-Shlomo I, Dor J, Ben-Rafael Z, Nebel L,
Mashiach S. Ageing of endometrium and oocytes: observa-
tions on conception and abortion rates in an egg donation
model. Fertil Steril 1991;56:1091-4.
18. Check JH, Nowroozi K, Choe J, Lurie D, Dietterich C . The
effect of endometrial thickness and echo pattern on in vitro
fertilisation outcome in donor oocyte-embryo transfer cycle.
Fertil Steril 1993;59:72-5.
19. Check JH, Askari HA, Fisher C, Vanaman L. The use of a
shared donor oocyte program to evaluate the effect of uterine
senescence. Fertil Steril 1994;61:252-6.
20. Meldrum DR. Female reproductive ageing-ovarian and uter-
ine factors. Fertil Steril 1993;59:1-5.
21. Barri PN, Martinez F, Coroleu B, Parera N, Veiga A. Manag-
ing nonresponders. In: Kempers RD, Cohen J, Haney AF,
Younger JB, editors. Fertility and reproductive medicine.
Proceedings of the XVI World Congress on Fertility and
Sterility; 1998 Oct 4-9; San Francisco, US. San Francisco:
Elsevier; 1998:127-37.
22. Chan YF, Ho PC, So WW, Yeung WS. Basal serum pituitary
hormone levels and outcome of in-vitro fertilisation utilizing
a flare nasal gonadotropin releasing hormone agonist and fixed
low-dose follicle-stimulating hormone/human menopausal
gonadotropin regimen. J Assist Reprod Genet 1993;10:251-4.
23. Balasch J, Creus M, Fabregues F, et al. Inhibin, follicle-
stimulating hormone, and age as predictors of ovarian response
in in-vitro fertilisation cycles stimulated with gonadotrophin-
releasing hormone agonist-gonadotrophin treatment. Am J
Obstet Gynecol 1996;175:1226-30.
24. Seifer DB, Lambert-Messercian G, Hogan JW, et al. Day 3
serum inhibin-B is predictive of assisted reproductive
technologies outcome. Fertil Steril 1997;67:110-4.
25. Smotrich BB, Widra EA, Gindoff PR, Levy MJ, Hall JL,
Stillman RJ. Prognostic value of day 3 estradiol on in-vitro
fertilisation outcome. Fertil Steril 1995;64:1136-40.
26. Hansen LM, Batzer FR, Gutmann JN, Corson SL, Kelly MP,
Gocial B. Evaluating ovarian reserve: follicle stimulating
hormone and oestradiol variability during cycle days 2-5.
Hum Reprod 1996;11:486-9.
27. Buyalos R, Daneshmand S, Brzechffa PR. Basal estradiol and
follicle stimulating hormone predict fecundity in women of
152      HKMJ Vol 6 No 2 June 2000
Lau et al
advanced reproductive age undergoing ovulation induction
therapy. Fertil Steril 1997;68:272-7.
28. Chang MY, Chiang CH, Chiu TH, Hsieh TT, Soong YK. The
antral follicle count predicts the outcome of pregnancy in a
controlled hyperstimulation/intrauterine insemination program.
J Assist Reprod Genet 1998;15:12-7.
29. Olivennes F, Righini C, Fanchin R, et al. A protocol using
a low dose of gonadotrophin-releasing hormone agonist
might be the best protocol for patients with high follicle
stimulating hormone concentrations on day 3. Hum Reprod
1996;11:1169-72.
30. Out HJ, Driessen SG, Mannaerts BH, Coelingh Bennink HJ.
Recombinant follicle-stimulating hormone (follitropin beta,
Puregon) yields higher pregnancy rates in in vitro fertilisation
than urinary gonadotrophins. Fertil Steril 1997;68:138-42.
31. Bergh C, Howles CM, Borg K. Recombinant human follicle-
stimulating hormone (r-hFSH; Gonal-F) versus highly purified
urinary FSH (metrodin HP): results of a randomized compara-
tive study in women undergoing assisted reproductive techniques.
Hum Reprod 1997;12:52-6.
